Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Bleijerveld OB"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yalçin Z; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Lam SY; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Peuscher MH; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., van der Torre J; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Zhu S; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Iyengar PV; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Salas-Lloret D; Department of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC, Leiden, the Netherlands., de Krijger I; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Moatti N; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., van der Lugt R; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Falcone M; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Cerutti A; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Bleijerveld OB; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., Hoekman L; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands., González-Prieto R; Department of Cell and Chemical Biology, Leiden University Medical Center, Einthovenweg 20, 2333 ZC, Leiden, the Netherlands.; Andalusian Center for Molecular Biology and regenerative Medicine (CABIMER), Universidad de Sevilla-CSIC-Universidad-Pablo de Olavide, Sevilla, Spain.; Departamento de Biología Celular, Facultad de Biología, Universidad de Sevilla, Sevilla, Spain., Jacobs JJL; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, the Netherlands. j.jacobs@nki.nl.
Publikováno v:
Nature communications [Nat Commun] 2024 Jun 12; Vol. 15 (1), pp. 5032. Date of Electronic Publication: 2024 Jun 12.
Autor:
Yang C; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Pataskar A; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: a.pataskar@nki.nl., Feng X; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Montenegro Navarro J; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Paniagua I; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Jacobs JJL; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Zaal EA; Division of Cell Biology, Metabolism & Cancer, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands., Berkers CR; Division of Cell Biology, Metabolism & Cancer, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands., Bleijerveld OB; NKI Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Agami R; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Erasmus MC, Department of Genetics, Rotterdam University, Rotterdam, the Netherlands. Electronic address: r.agami@nki.nl.
Publikováno v:
Molecular cell [Mol Cell] 2024 May 16; Vol. 84 (10), pp. 1904-1916.e7.
Autor:
Dias MH; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Liudkovska V; IMol Polish Academy of Sciences, Warsaw, Poland., Montenegro Navarro J; Division of Oncogenomics and Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Giebel L; Division of Oncogenomics and Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Champagne J; Division of Oncogenomics and Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Papagianni C; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bleijerveld OB; Proteomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands., Velds A; Central Genomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands., Agami R; Division of Oncogenomics and Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bernards R; Division of Molecular Carcinogenesis and Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. r.bernards@nki.nl., Cieśla M; IMol Polish Academy of Sciences, Warsaw, Poland. m.ciesla@imol.institute.
Publikováno v:
EMBO reports [EMBO Rep] 2024 May; Vol. 25 (5), pp. 2220-2238. Date of Electronic Publication: 2024 Apr 10.
Autor:
Lin CP; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Levy PL; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Tumor Immunology and Immunotherapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Alflen A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany; Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany., Apriamashvili G; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Bleijerveld OB; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Alkan F; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Malka Y; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Hoekman L; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Markovits E; Ella Lemelbaum Institute for Immuno-oncology and Melanoma, Sheba Medical Center, Ramat Gan 52612, Israel; Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel., George A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Traets JJH; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Krijgsman O; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van Vliet A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Poźniak J; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000 Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium., Pulido-Vicuña CA; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000 Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium., de Bruijn B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van Hal-van Veen SE; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Boshuizen J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van der Helm PW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Díaz-Gómez J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Warda H; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Behrens LM; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Mardesic P; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Dehni B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Visser NL; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Marine JC; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000 Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium., Markel G; Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel; Davidoff Cancer Center and Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center, Petach Tikva 4941492, Israel., Faller WJ; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Altelaar M; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Biomolecular Mass Spectrometry and Proteomics, Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, the Netherlands., Agami R; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Besser MJ; Ella Lemelbaum Institute for Immuno-oncology and Melanoma, Sheba Medical Center, Ramat Gan 52612, Israel; Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel; Davidoff Cancer Center and Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center, Petach Tikva 4941492, Israel; Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Department of Pathology, VU University Amsterdam, 1081 HV Amsterdam, the Netherlands. Electronic address: d.peeper@nki.nl.
Publikováno v:
Cancer cell [Cancer Cell] 2024 Apr 08; Vol. 42 (4), pp. 623-645.e10. Date of Electronic Publication: 2024 Mar 14.
Autor:
Gan C; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Wang J; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Wang Y; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Martínez-Chávez A; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Hillebrand M; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., de Vries N; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Beukers J; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Lebre MC; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Wagenaar E; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Klarenbeek S; Experimental Animal Pathology Facility, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Bleijerveld OB; Proteomics Core Facility, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Song JY; Experimental Animal Pathology Facility, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands., Altelaar M; Proteomics Core Facility, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, and Netherlands Proteomics Center, Padualaan 8, Utrecht 3584 CH, The Netherlands., Beijnen JH; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CS, the Netherlands., Schinkel AH; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands. Electronic address: a.schinkel@nki.nl.
Publikováno v:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Aug; Vol. 164, pp. 114956. Date of Electronic Publication: 2023 May 31.
Autor:
Yalçin Z; Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Koot D; Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bezstarosti K; Proteomics Center, Erasmus Medical Center, Rotterdam, The Netherlands., Salas-Lloret D; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands., Bleijerveld OB; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Boersma V; Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Falcone M; Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., González-Prieto R; Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, The Netherlands; Genome Proteomics Laboratory, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), University of Seville, Seville, Spain; Department of Cell Biology, University of Seville, Seville, Spain., Altelaar M; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Netherlands Proteomics Center, University of Utrecht, Utrecht, The Netherlands., Demmers JAA; Proteomics Center, Erasmus Medical Center, Rotterdam, The Netherlands., Jacobs JJL; Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: j.jacobs@nki.nl.
Publikováno v:
Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2023 Jun; Vol. 22 (6), pp. 100548. Date of Electronic Publication: 2023 Apr 13.
Autor:
Haahr P; Division of Biochemistry, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands.; Novo Nordisk Foundation Center for Protein Research (NNF-CPR), Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark., Galli RA; Department of Physiology, Amsterdam UMC (VUmc), 1081HV Amsterdam, Netherlands., van den Hengel LG; Division of Biochemistry, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands.; Oncode Institute, Division of Biochemistry, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands., Bleijerveld OB; Proteomics Facility, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands., Kazokaitė-Adomaitienė J; Protein Facility, Division of Biochemistry, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands., Song JY; Animal Pathology, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands., Kroese LJ; Animal Modeling Facility, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands., Krimpenfort P; Animal Modeling Facility, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands., Baltissen MP; Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University Nijmegen, 6525GA Nijmegen, Netherlands., Vermeulen M; Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University Nijmegen, 6525GA Nijmegen, Netherlands., Ottenheijm CAC; Department of Physiology, Amsterdam UMC (VUmc), 1081HV Amsterdam, Netherlands., Brummelkamp TR; Division of Biochemistry, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands.; Oncode Institute, Division of Biochemistry, Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands.
Publikováno v:
Science (New York, N.Y.) [Science] 2022 Sep 30; Vol. 377 (6614), pp. 1533-1537. Date of Electronic Publication: 2022 Sep 29.
Autor:
Zuidema A; Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Atherton P; Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kreft M; Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Hoekman L; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Bleijerveld OB; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Nagaraj N; Mass Spectrometry Core Facility at the Max-Planck Institute of Biochemistry, Planegg, Germany., Chen N; Department of Molecular Medicine, Max-Planck Institute of Biochemistry, Planegg, Germany., Fässler R; Department of Molecular Medicine, Max-Planck Institute of Biochemistry, Planegg, Germany., Sonnenberg A; Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Publikováno v:
The Journal of cell biology [J Cell Biol] 2022 Aug 01; Vol. 221 (8). Date of Electronic Publication: 2022 Jun 10.